Edistride

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

dapagliflozin propandiol monohidrat

Available from:

AstraZeneca AB

ATC code:

A10BK01

INN (International Name):

dapagliflozin

Therapeutic group:

Zdravila, ki se uporabljajo pri diabetesu

Therapeutic area:

Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic

Therapeutic indications:

Type 2 diabetes mellitusEdistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. Heart failureEdistride is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseEdistride is indicated in adults for the treatment of chronic kidney disease.

Product summary:

Revision: 22

Authorization status:

Pooblaščeni

Authorization date:

2015-11-09

Patient Information leaflet

                                46
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
AstraZeneca AB
SE-151 85 Södertälje
Švedska
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET)
EU/1/15/1052/001 14 filmsko obloženih tablet
EU/1/15/1052/002 28 filmsko obloženih tablet
EU/1/15/1052/003 98 filmsko obloženih tablet
EU/1/15/1052/004 30 x 1 (enkratni odmerek) filmsko obložena tableta
EU/1/15/1052/005 90 x 1 (enkratni odmerek) filmsko obložena tableta
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
edistride 5 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
47
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PERFORIRANI PRETISNI OMOTI ZA POSAMEZNI ODMEREK 5 MG
1.
IME ZDRAVILA
Edistride 5 mg tablete
dapagliflozin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
AstraZeneca AB
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
48
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
NEPERFORIRANI KOLEDARSKI PRETISNI OMOTI 5 MG
1.
IME ZDRAVILA
Edistride 5 mg tablete
dapagliflozin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
AstraZeneca AB
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
Ponedeljek Torek Sreda Četrtek Petek Sobota Nedelja
49
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA 10 MG
1.
IME ZDRAVILA
Edistride 10 mg filmsko obložene tablete
dapagliflozin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena tableta vsebuje dapagliflozin propandiol monohidrat, kolikor ga
ustreza 10 mg dapagliflozina.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo. Za dodatne informacije glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
14 filmsko obloženih tablet
28 filmsko obloženih tablet
30 x 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Edistride 5 mg filmsko obložene tablete
Edistride 10 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Edistride 5 mg filmsko obložene tablete
Ena tableta vsebuje dapagliflozin propandiol monohidrat, kolikor ga
ustreza 5 mg dapagliflozina.
_Pomožna snov z znanim učinkom_
Ena 5 mg tableta vsebuje 25 mg laktoze.
Edistride 10 mg filmsko obložene tablete
Ena tableta vsebuje dapagliflozin propandiol monohidrat, kolikor ga
ustreza 10 mg dapagliflozina.
_Pomožna snov z znanim učinkom_
Ena 10 mg tableta vsebuje 50 mg laktoze.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Edistride 5 mg filmsko obložene tablete
Rumene, bikonveksne, okrogle, filmsko obložene tablete s premerom 0,7
cm in z vtisnjeno oznako "5"
na eni strani ter "1427" na drugi strani.
Edistride 10 mg filmsko obložene tablete
Rumene, bikonveksne, rombaste, filmsko obložene tablete s
približnimi diagonalami 1,1 x 0,8 cm in z
vtisnjeno oznako "10" na eni strani ter "1428" na drugi strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Sladkorna bolezen tipa 2
Zdravilo Edistride je indicirano pri odraslih in otrocih starih 10 let
in več za zdravljenje nezadostno
urejene sladkorne bolezni tipa 2 kot dodatek dieti in telesni
dejavnosti
-
kot samostojno zdravljenje (monoterapija), če metformin zaradi
intolerance ni primeren.
-
kot dodatek drugim zdravilom za zdravljenje sladkorne bolezni tipa 2.
Za rezultate študij o kombinacijah zdravil, učinkih na urejenost
glikemije, srčno-žilnih in ledvičnih
dogodkih ter proučevanih populacijah glejte poglavja 4.4, 4.5 in 5.1.
3
Srčno popuščanje
Zdravilo Edistride je indicirano pri odraslih za zdravljenje
simptomatskega kroničnega srčnega
popuščanja.
Kronična ledvična bolezen
Zdravilo Edistride je indicirano pri odraslih za zdravljenje kronične
ledvične bolezni.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Sladkorna bolezen tipa 2_
Priporočeni 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-02-2024
Public Assessment Report Public Assessment Report Bulgarian 20-01-2022
Patient Information leaflet Patient Information leaflet Spanish 07-02-2024
Public Assessment Report Public Assessment Report Spanish 20-01-2022
Patient Information leaflet Patient Information leaflet Czech 07-02-2024
Public Assessment Report Public Assessment Report Czech 20-01-2022
Patient Information leaflet Patient Information leaflet Danish 07-02-2024
Public Assessment Report Public Assessment Report Danish 20-01-2022
Patient Information leaflet Patient Information leaflet German 07-02-2024
Public Assessment Report Public Assessment Report German 20-01-2022
Patient Information leaflet Patient Information leaflet Estonian 07-02-2024
Public Assessment Report Public Assessment Report Estonian 20-01-2022
Patient Information leaflet Patient Information leaflet Greek 07-02-2024
Public Assessment Report Public Assessment Report Greek 20-01-2022
Patient Information leaflet Patient Information leaflet English 07-02-2024
Public Assessment Report Public Assessment Report English 06-03-2023
Patient Information leaflet Patient Information leaflet French 07-02-2024
Public Assessment Report Public Assessment Report French 20-01-2022
Patient Information leaflet Patient Information leaflet Italian 07-02-2024
Public Assessment Report Public Assessment Report Italian 20-01-2022
Patient Information leaflet Patient Information leaflet Latvian 07-02-2024
Public Assessment Report Public Assessment Report Latvian 20-01-2022
Patient Information leaflet Patient Information leaflet Lithuanian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-02-2024
Public Assessment Report Public Assessment Report Lithuanian 20-01-2022
Patient Information leaflet Patient Information leaflet Hungarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 07-02-2024
Public Assessment Report Public Assessment Report Hungarian 20-01-2022
Patient Information leaflet Patient Information leaflet Maltese 07-02-2024
Public Assessment Report Public Assessment Report Maltese 20-01-2022
Patient Information leaflet Patient Information leaflet Dutch 07-02-2024
Public Assessment Report Public Assessment Report Dutch 20-01-2022
Patient Information leaflet Patient Information leaflet Polish 07-02-2024
Public Assessment Report Public Assessment Report Polish 20-01-2022
Patient Information leaflet Patient Information leaflet Portuguese 07-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 07-02-2024
Public Assessment Report Public Assessment Report Portuguese 20-01-2022
Patient Information leaflet Patient Information leaflet Romanian 07-02-2024
Public Assessment Report Public Assessment Report Romanian 20-01-2022
Patient Information leaflet Patient Information leaflet Slovak 07-02-2024
Public Assessment Report Public Assessment Report Slovak 20-01-2022
Patient Information leaflet Patient Information leaflet Finnish 07-02-2024
Public Assessment Report Public Assessment Report Finnish 20-01-2022
Patient Information leaflet Patient Information leaflet Swedish 07-02-2024
Public Assessment Report Public Assessment Report Swedish 20-01-2022
Patient Information leaflet Patient Information leaflet Norwegian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 07-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 07-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 07-02-2024
Patient Information leaflet Patient Information leaflet Croatian 07-02-2024
Public Assessment Report Public Assessment Report Croatian 20-01-2022

Search alerts related to this product

View documents history